Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almansour-001 pDNA COVID-19 Vaccine in Healthy Adults
NCT05171946Phase 1Unknown
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
01
Overview
Phase 1, randomised trial of Almansour-001 in coronavirus disease 2019 (COVID-19) (3 cohorts). Primary endpoints: Percentage and frequency of study subjects reporting local reaction, Percentage of study subjects reporting systematic reaction and 6 more. Status: unknown.
02
Drugs
Almansour-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05171946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171946.